Juan Min, Ying Zhao, Jie Du, Yongzhong Ning, Zhiqiang Wu
{"title":"Arthritis caused by Cryptococcus neoformans infection: A case report","authors":"Juan Min, Ying Zhao, Jie Du, Yongzhong Ning, Zhiqiang Wu","doi":"10.3892/br.2023.1694","DOIUrl":"https://doi.org/10.3892/br.2023.1694","url":null,"abstract":"","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"158 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139258426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suvinai Jiraboonsri, Panicha Hemvipat, Supitcha Kamolratanakul, Narumol Bhummaphan, T. Siritientong, N. Kitkumthorn, A. Mutirangura, Jiraroch Meevassana
{"title":"CpG methylation changes in Alu repetitive sequences in normal aging due to diastolic hypertension in human dermal fibroblasts from the facial area","authors":"Suvinai Jiraboonsri, Panicha Hemvipat, Supitcha Kamolratanakul, Narumol Bhummaphan, T. Siritientong, N. Kitkumthorn, A. Mutirangura, Jiraroch Meevassana","doi":"10.3892/br.2023.1693","DOIUrl":"https://doi.org/10.3892/br.2023.1693","url":null,"abstract":"","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"84 3-4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139263001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ari Abdullah, Fahmi Kakamad, Aland Abdullah, Soran Tahir, Rezheen Rashid, Jihad Hama, Bnar Hama Amin, Pavel Kareem
Pulmonary osseous metaplasia is a disease in which mature bone is found within the parenchyma of the lung. The current study presents a case of pulmonary osseous metaplasia in a 64‑year‑old female. The patient was previously diagnosed with transitional cell carcinoma (TCC) of the lower ureter. During a routine check‑up, an enhancing basal lung nodule was found on chest computed tomography scan, which was suspected to be metastatic lung disease. The patient underwent a thoracoscopic resection of the nodule. The histopathological examination of the specimen confirmed it to be myeloid osseous metaplasia. The disease usually has no significant complications and can also be found in association with other pulmonary diseases. Very limited information is available on the phenomenon; therefore, there is no exact treatment guide for clinicians to follow. In conclusion, myeloid osseous metaplasia of the lung is a rare finding, and based on this report, it may be associated with TCC.
{"title":"Myeloid osseous metaplasia of the lung: A case report","authors":"Ari Abdullah, Fahmi Kakamad, Aland Abdullah, Soran Tahir, Rezheen Rashid, Jihad Hama, Bnar Hama Amin, Pavel Kareem","doi":"10.3892/br.2023.1691","DOIUrl":"https://doi.org/10.3892/br.2023.1691","url":null,"abstract":"Pulmonary osseous metaplasia is a disease in which mature bone is found within the parenchyma of the lung. The current study presents a case of pulmonary osseous metaplasia in a 64‑year‑old female. The patient was previously diagnosed with transitional cell carcinoma (TCC) of the lower ureter. During a routine check‑up, an enhancing basal lung nodule was found on chest computed tomography scan, which was suspected to be metastatic lung disease. The patient underwent a thoracoscopic resection of the nodule. The histopathological examination of the specimen confirmed it to be myeloid osseous metaplasia. The disease usually has no significant complications and can also be found in association with other pulmonary diseases. Very limited information is available on the phenomenon; therefore, there is no exact treatment guide for clinicians to follow. In conclusion, myeloid osseous metaplasia of the lung is a rare finding, and based on this report, it may be associated with TCC.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"16 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134991545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Protein induced by vitamin K (VK) absence‑II (PIVKA‑II) is a sensitive marker for diagnosing hepatoma but is occasionally detected in patients without hepatoma Here, the clinical significance of serum PIVKA‑II levels in patients who were not administered warfarin and did not have hepatoma or liver disease were evaluated. As VK is related to muscle and bone metabolism, PIVKA‑II and clinical factors related to bone and muscle were compared. A total of 441 patients with various liver diseases were evaluated. Of these, 236 patients were female. Clinical factors and anthropometric measurements were obtained for each participant during outpatient visits. Among the clinical factors, type I procollagen N‑propeptide (P1NP), a low titer of undercarboxylated osteocalcin (ucOC), and 25(OH) vitamin D (VD) were used as bone metabolic markers, and SARC‑F and grip strength were used as muscle‑related markers. Serum PIVKA‑II levels above the upper limit were associated with Child B/C (Child‑Pugh score), high titers of total P1NP, and low titers of ucOC in females, and alcohol‑related liver disease and low VD in males. The titer of PIVKA‑II were associated with immunoglobulin (Ig) A and prothrombin time (PT)‑international normalized ratio (INR) in females, and fibrosis‑4‑4, IgG, total bilirubin, PT‑INR, and SARC‑F in males. Elevated PIVKA‑II levels were associated with abnormal bone physiology in females, weak muscles in males, and severe liver disease in both sexes. Assessing PIVKA‑II may assist in evaluating the clinical and bone‑muscle metabolic stages in liver disease. Nutrition and supplementation with fat‑soluble vitamins, including VK and VD may thus serve as a potential method to alleviate or prevent bone‑muscle pathophysiology in patients with liver disease.
{"title":"PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease","authors":"Takuya Honda, Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Tetsurou Honda, Hiroyuki Yajima, Osamu Miyazaki, Yasutaka Kuribayashi, Tomonari Ikeda, Takuma Okamura, Kazuyoshi Nagata, Kazuhiko Nakao","doi":"10.3892/br.2023.1690","DOIUrl":"https://doi.org/10.3892/br.2023.1690","url":null,"abstract":"Protein induced by vitamin K (VK) absence‑II (PIVKA‑II) is a sensitive marker for diagnosing hepatoma but is occasionally detected in patients without hepatoma Here, the clinical significance of serum PIVKA‑II levels in patients who were not administered warfarin and did not have hepatoma or liver disease were evaluated. As VK is related to muscle and bone metabolism, PIVKA‑II and clinical factors related to bone and muscle were compared. A total of 441 patients with various liver diseases were evaluated. Of these, 236 patients were female. Clinical factors and anthropometric measurements were obtained for each participant during outpatient visits. Among the clinical factors, type I procollagen N‑propeptide (P1NP), a low titer of undercarboxylated osteocalcin (ucOC), and 25(OH) vitamin D (VD) were used as bone metabolic markers, and SARC‑F and grip strength were used as muscle‑related markers. Serum PIVKA‑II levels above the upper limit were associated with Child B/C (Child‑Pugh score), high titers of total P1NP, and low titers of ucOC in females, and alcohol‑related liver disease and low VD in males. The titer of PIVKA‑II were associated with immunoglobulin (Ig) A and prothrombin time (PT)‑international normalized ratio (INR) in females, and fibrosis‑4‑4, IgG, total bilirubin, PT‑INR, and SARC‑F in males. Elevated PIVKA‑II levels were associated with abnormal bone physiology in females, weak muscles in males, and severe liver disease in both sexes. Assessing PIVKA‑II may assist in evaluating the clinical and bone‑muscle metabolic stages in liver disease. Nutrition and supplementation with fat‑soluble vitamins, including VK and VD may thus serve as a potential method to alleviate or prevent bone‑muscle pathophysiology in patients with liver disease.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"57 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136346824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present study aimed to investigate the accuracy of new noninvasive markers in predicting liver fibrosis among individuals with primary biliary cholangitis (PBC). This retrospective analysis included subjects with PBC who had liver biopsies. Scheuer's classification was used to determine the fibrosis stage. The bilirubin to albumin (Alb) ratio (BAR), fibrosis index based on the four factors (FIB‑4), γ‑glutamyl transpeptidase to platelet (PLT) ratio (GPR), red cell distribution width to PLT ratio (RPR), aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), AST to PLT ratio index (APRI) and total bilirubin to PLT ratio (TPR) were calculated based on the laboratory parameters. A novel index called BARP was conceived as BAR x RPR. A total of 78 individuals with PBC were included in the study, 84.6% of whom had significant fibrosis, 30.8% had advanced fibrosis and 15.4% had cirrhosis. In the multivariate analysis, Alb was determined to be an independent predictor of advanced fibrosis (odds ratio=0.823, P=0.034). The area under the receiver operating characteristic curves (AUROCs) of the BAR, GPR, TPR and BARP were statistically significant in predicting severe fibrosis (P<0.05) and were 0.747, 0.684, 0.693 and 0.696, respectively. In assessing advanced fibrosis, the AUROCs for the AAR, APRI, BAR, FIB‑4, RPR, TPR and BARP were 0.726, 0.650, 0.742, 0.716, 0.670, 0.735 and 0.750, respectively. The AUROCs for the APRI, BAR, FIB‑4, RPR, TPR and BARP for cirrhosis prediction were 0.776, 0.753, 0.821, 0.819, 0.808 and 0.832, respectively. By comparing the AUROCs, it was demonstrated that the diagnostic capabilities of the BARP (P=0.021) and TPR (P=0.044) were superior to those of the APRI in predicting advanced fibrosis. In conclusion, the BAR, BARP and TPR were of predictive value for the grade of liver fibrosis in PBC and Alb had a diagnostic value in identifying early fibrosis. The aforementioned noninvasive indices may be used for predicting histologic stages of PBC.
{"title":"Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis","authors":"Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li","doi":"10.3892/br.2023.1689","DOIUrl":"https://doi.org/10.3892/br.2023.1689","url":null,"abstract":"The present study aimed to investigate the accuracy of new noninvasive markers in predicting liver fibrosis among individuals with primary biliary cholangitis (PBC). This retrospective analysis included subjects with PBC who had liver biopsies. Scheuer's classification was used to determine the fibrosis stage. The bilirubin to albumin (Alb) ratio (BAR), fibrosis index based on the four factors (FIB‑4), γ‑glutamyl transpeptidase to platelet (PLT) ratio (GPR), red cell distribution width to PLT ratio (RPR), aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), AST to PLT ratio index (APRI) and total bilirubin to PLT ratio (TPR) were calculated based on the laboratory parameters. A novel index called BARP was conceived as BAR x RPR. A total of 78 individuals with PBC were included in the study, 84.6% of whom had significant fibrosis, 30.8% had advanced fibrosis and 15.4% had cirrhosis. In the multivariate analysis, Alb was determined to be an independent predictor of advanced fibrosis (odds ratio=0.823, P=0.034). The area under the receiver operating characteristic curves (AUROCs) of the BAR, GPR, TPR and BARP were statistically significant in predicting severe fibrosis (P<0.05) and were 0.747, 0.684, 0.693 and 0.696, respectively. In assessing advanced fibrosis, the AUROCs for the AAR, APRI, BAR, FIB‑4, RPR, TPR and BARP were 0.726, 0.650, 0.742, 0.716, 0.670, 0.735 and 0.750, respectively. The AUROCs for the APRI, BAR, FIB‑4, RPR, TPR and BARP for cirrhosis prediction were 0.776, 0.753, 0.821, 0.819, 0.808 and 0.832, respectively. By comparing the AUROCs, it was demonstrated that the diagnostic capabilities of the BARP (P=0.021) and TPR (P=0.044) were superior to those of the APRI in predicting advanced fibrosis. In conclusion, the BAR, BARP and TPR were of predictive value for the grade of liver fibrosis in PBC and Alb had a diagnostic value in identifying early fibrosis. The aforementioned noninvasive indices may be used for predicting histologic stages of PBC.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"62 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136347756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaoqing Chen, Chongyang Ren, Zhisheng Zhou, Jintao Chen, Xulong Fan, Ruijian Liang, Haiyan Liu, Jing Zhu, Jin Gong
Sialyltransferases responsible for glycoprotein sialylation are key regulators in cancer progression. Although ST3 β‑galactoside α‑2,3‑sialyltransferase 4 (ST3GAL4), an important sialyltransferase, is upregulated in breast cancer, its biological functions remain unclear. The present study aimed to investigate the impact and mechanisms of ST3GAL4 on glycolysis in breast cancer. ST3GAL4 expression was examined in tumor tissue specimens and microarrays and breast cancer cell lines BT‑474, SKBR3, MCF‑7, and T47D. ST3GAL4 was silenced or overexpressed by lentivirus transfection in breast cancer cells. Cell viability and cell cycle were evaluated by Cell Counting Kit‑8 and flow cytometry, respectively. Extracellular acidification rate, glucose uptake and lactate production were used for glycolysis assessment. ST3GAL4 was consistently upregulated in tumor tissues and cell lines of breast cancer. High ST3GAL4 expression was associated with poor prognosis of patients with breast cancer. Cell viability was decreased, cell cycle progression was inhibited and glycolysis was inhibited in ST3GAL4‑silenced cells compared with control cells. ST3GAL4 silencing led to suppression of tumor growth and cell proliferation in xenograft mouse models. ST3GAL4 overexpression promoted cell viability and accelerated cell cycle, which were reversed by glycolysis inhibitor. The study provided invivo and invitro evidence that ST3GAL4 promoted cell viability and tumor growth by regulating the glycolysis pathway in breast cancer. ST3GAL4 inhibition may serve as a strategy for treatment of breast cancer.
{"title":"Loss of ST3GAL4 exhibits an anticancer effect in breast cancer via the glycolysis pathway","authors":"Xiaoqing Chen, Chongyang Ren, Zhisheng Zhou, Jintao Chen, Xulong Fan, Ruijian Liang, Haiyan Liu, Jing Zhu, Jin Gong","doi":"10.3892/br.2023.1688","DOIUrl":"https://doi.org/10.3892/br.2023.1688","url":null,"abstract":"Sialyltransferases responsible for glycoprotein sialylation are key regulators in cancer progression. Although ST3 β‑galactoside α‑2,3‑sialyltransferase 4 (ST3GAL4), an important sialyltransferase, is upregulated in breast cancer, its biological functions remain unclear. The present study aimed to investigate the impact and mechanisms of ST3GAL4 on glycolysis in breast cancer. ST3GAL4 expression was examined in tumor tissue specimens and microarrays and breast cancer cell lines BT‑474, SKBR3, MCF‑7, and T47D. <em>ST3GAL4</em> was silenced or overexpressed by lentivirus transfection in breast cancer cells. Cell viability and cell cycle were evaluated by Cell Counting Kit‑8 and flow cytometry, respectively. Extracellular acidification rate, glucose uptake and lactate production were used for glycolysis assessment. ST3GAL4 was consistently upregulated in tumor tissues and cell lines of breast cancer. High ST3GAL4 expression was associated with poor prognosis of patients with breast cancer. Cell viability was decreased, cell cycle progression was inhibited and glycolysis was inhibited in <em>ST3GAL4</em>‑silenced cells compared with control cells. <em>ST3GAL4</em> silencing led to suppression of tumor growth and cell proliferation in xenograft mouse models. ST3GAL4 overexpression promoted cell viability and accelerated cell cycle, which were reversed by glycolysis inhibitor. The study provided <em>in</em> <em>vivo</em> and <em>in</em> <em>vitro</em> evidence that ST3GAL4 promoted cell viability and tumor growth by regulating the glycolysis pathway in breast cancer. ST3GAL4 inhibition may serve as a strategy for treatment of breast cancer.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135819843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Preciado‑Ortiz, Erika Martinez‑Lopez, Roberto Rodriguez‑Echevarría, Mariana Perez‑Robles, Gildardo Gembe‑Olivarez, Juan Rivera‑Valdés
Obesity is defined as excessive fat accumulation that can be detrimental to health and currently affects a large part of the global population. Obesity arises from excessive energy intake along with a sedentary lifestyle and leads to adipocytes with aggravated hypertrophy. Strategies have been designed to prevent and treat obesity. Nutrigenomics may serve a role in prevention of obesity using bioactive compounds present in certain foods with anti‑obesogenic effects. Ginger (Zingiber officinale Roscoe) contains gingerols, key bioactive compounds that inhibit hypertrophy and hyperplasia of adipocytes. The present study aimed to evaluate the antiadipogenic activity of 10‑gingerol (10‑G) in the 3T3‑L1 cell line. Three study groups were formed: Negative (3T3‑L1 preadipocytes) and positive control (mature 3T3‑L1 adipocytes) and 10‑G (3T3‑L1 preadipocytes stimulated with 10‑G during adipogenic differentiation). Cell viability and lipid content were evaluated by MTT assay and Oil Red O staining, respectively. mRNA expression of CCAAT enhancer‑binding protein α (C/ebpα), peroxisome proliferator‑activated receptor γ (Pparγ), mechanistic target of rapamycin complex (Mtor), sterol regulatory element binding transcription factor 1 (Srebf1), acetyl‑coenzyme A carboxylase (Acaca), fatty acid binding protein 4 (Fabp4), and 18S rRNA (Rn18s), was quantified by quantitative PCR. The protein expression of C/EPBα was analyzed by western blot. In the 10‑G group, lipid content was decreased by 28.83% (P<0.0001) compared with the positive control; notably, cell viability was not affected (P=0.336). The mRNA expression in the 10‑G group was higher for C/ebpα (P<0.001) and lower for Acaca (P<0.001), Fabp4 (P<0.001), Mtor (P<0.0001) and Srebf1 (P<0.0001) compared with the positive control group, while gene expression of Pparγ did not present significant changes. The presence of 10‑G notably decreased C/EBPα protein levels in 3T3‑L1 adipocytes. In summary, the antiadipogenic effect of 10‑G during the differentiation of 3T3‑L1 cells into adipocytes may be explained by mRNA downregulation of adipogenic transcriptional factors and lipid metabolism‑associated genes.
{"title":"10‑Gingerol, a novel ginger compound, exhibits antiadipogenic effects without compromising cell viability in 3T3‑L1 cells","authors":"María Preciado‑Ortiz, Erika Martinez‑Lopez, Roberto Rodriguez‑Echevarría, Mariana Perez‑Robles, Gildardo Gembe‑Olivarez, Juan Rivera‑Valdés","doi":"10.3892/br.2023.1687","DOIUrl":"https://doi.org/10.3892/br.2023.1687","url":null,"abstract":"Obesity is defined as excessive fat accumulation that can be detrimental to health and currently affects a large part of the global population. Obesity arises from excessive energy intake along with a sedentary lifestyle and leads to adipocytes with aggravated hypertrophy. Strategies have been designed to prevent and treat obesity. Nutrigenomics may serve a role in prevention of obesity using bioactive compounds present in certain foods with anti‑obesogenic effects. Ginger (<em>Zingiber officinale Roscoe</em>) contains gingerols, key bioactive compounds that inhibit hypertrophy and hyperplasia of adipocytes. The present study aimed to evaluate the antiadipogenic activity of 10‑gingerol (10‑G) in the 3T3‑L1 cell line. Three study groups were formed: Negative (3T3‑L1 preadipocytes) and positive control (mature 3T3‑L1 adipocytes) and 10‑G (3T3‑L1 preadipocytes stimulated with 10‑G during adipogenic differentiation). Cell viability and lipid content were evaluated by MTT assay and Oil Red O staining, respectively. mRNA expression of CCAAT enhancer‑binding protein α (<em>C/ebpα</em>), peroxisome proliferator‑activated receptor γ (<em>Pparγ</em>), mechanistic target of rapamycin complex (<em>Mtor</em>), sterol regulatory element binding transcription factor 1 (<em>Srebf1</em>), acetyl‑coenzyme A carboxylase (<em>Acaca</em>), fatty acid binding protein 4 (<em>Fabp4</em>), and 18S rRNA (<em>Rn18s</em>), was quantified by quantitative PCR. The protein expression of C/EPBα was analyzed by western blot. In the 10‑G group, lipid content was decreased by 28.83% (P<0.0001) compared with the positive control; notably, cell viability was not affected (P=0.336). The mRNA expression in the 10‑G group was higher for <em>C/ebpα</em> (P<0.001) and lower for <em>Acaca</em> (P<0.001), <em>Fabp4</em> (P<0.001), <em>Mtor</em> (P<0.0001) and <em>Srebf1</em> (P<0.0001) compared with the positive control group, while gene expression of <em>Pparγ</em> did not present significant changes. The presence of 10‑G notably decreased C/EBPα protein levels in 3T3‑L1 adipocytes. In summary, the antiadipogenic effect of 10‑G during the differentiation of 3T3‑L1 cells into adipocytes may be explained by mRNA downregulation of adipogenic transcriptional factors and lipid metabolism‑associated genes.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"37 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135271951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jing-Bo Wu, Xiao-Jing Li, Hui Liu, Yong-Juan Liu, Xiu-Ping Liu
The relationships of KRAS, NRAS, BRAF and PIK3CA gene mutations with the clinicopathological features and prognosis of colorectal cancer (CRC) in patient are lacking. Furthermore, the role of ring finger protein 215 (RNF215) in CRC patients with KRAS, NRAS, BRAF and PIK3CA mutations remains unclear. In the present study, 182 surgical resection specimens from patients with primary CRC for retrospective analysis, were collected. KRAS/NRAS/BRAF/PIK3CA gene mutations were confirmed by an amplification‑refractory mutation system. Immunohistochemistry (IHC) was conducted to confirm KRAS, NRAS, BRAF and PIK3CA protein expression. RNF215 expression in patients with CRC was evaluated using TIMER 2.0 database and IHC. The individual mutation rates of KRAS, NRAS, BRAF and PIK3CA were 40.7% (74/182), 4.4% (8/182), 4.4% (8/182) and 3.3% (6/182), respectively. The KRAS exon 2 mutation rate was the highest (61.5%, 64/104), and these mutations mainly occurred at codons 12 and 13. KRAS/NRAS/BRAF/PIK3CA wild‑type CRC patients had significantly longer overall survival and disease‑free survival than mutated KRAS/NRAS/BRAF/PIK3CA CRC patients (P<0.05). Overall, 45.4% (5/11) of patients with PIK3CA mutations had concomitant KRAS mutations. The KRAS/NRAS/BRAF/PIK3CA gene mutation rate in patients with lymph node metastasis (76.1%, 35/46) was significantly higher than that in patients without lymph node metastasis (50.8%, 69/136) (P=0.0027). There were no significant differences in IHC expression between patients with and without KRAS, NRAS, BRAF and PIK3CA mutations (P>0.05). The TIMER 2.0 analysis showed that RNF215 expression was significantly higher in the mutated BRAF group than in the wild‑type BRAF group in CRC (P<0.05). In conclusion, KRAS is the most commonly mutated gene, and KRAS mutations may be a poor prognostic factor for patients with CRC. KRAS wild‑type patient resistance may be related to PIK3CA gene mutations, although this needs further verification in larger cohorts. BRAF mutations may be associated with RNF215 expression in patients with CRC.
{"title":"Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer","authors":"Jing-Bo Wu, Xiao-Jing Li, Hui Liu, Yong-Juan Liu, Xiu-Ping Liu","doi":"10.3892/br.2023.1686","DOIUrl":"https://doi.org/10.3892/br.2023.1686","url":null,"abstract":"The relationships of KRAS, NRAS, BRAF and PIK3CA gene mutations with the clinicopathological features and prognosis of colorectal cancer (CRC) in patient are lacking. Furthermore, the role of ring finger protein 215 (RNF215) in CRC patients with KRAS, NRAS, BRAF and PIK3CA mutations remains unclear. In the present study, 182 surgical resection specimens from patients with primary CRC for retrospective analysis, were collected. KRAS/NRAS/BRAF/PIK3CA gene mutations were confirmed by an amplification‑refractory mutation system. Immunohistochemistry (IHC) was conducted to confirm KRAS, NRAS, BRAF and PIK3CA protein expression. RNF215 expression in patients with CRC was evaluated using TIMER 2.0 database and IHC. The individual mutation rates of KRAS, NRAS, BRAF and PIK3CA were 40.7% (74/182), 4.4% (8/182), 4.4% (8/182) and 3.3% (6/182), respectively. The KRAS exon 2 mutation rate was the highest (61.5%, 64/104), and these mutations mainly occurred at codons 12 and 13. KRAS/NRAS/BRAF/PIK3CA wild‑type CRC patients had significantly longer overall survival and disease‑free survival than mutated KRAS/NRAS/BRAF/PIK3CA CRC patients (P<0.05). Overall, 45.4% (5/11) of patients with PIK3CA mutations had concomitant KRAS mutations. The KRAS/NRAS/BRAF/PIK3CA gene mutation rate in patients with lymph node metastasis (76.1%, 35/46) was significantly higher than that in patients without lymph node metastasis (50.8%, 69/136) (P=0.0027). There were no significant differences in IHC expression between patients with and without KRAS, NRAS, BRAF and PIK3CA mutations (P>0.05). The TIMER 2.0 analysis showed that RNF215 expression was significantly higher in the mutated BRAF group than in the wild‑type BRAF group in CRC (P<0.05). In conclusion, KRAS is the most commonly mutated gene, and KRAS mutations may be a poor prognostic factor for patients with CRC. KRAS wild‑type patient resistance may be related to PIK3CA gene mutations, although this needs further verification in larger cohorts. BRAF mutations may be associated with RNF215 expression in patients with CRC.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"40 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135813321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The timely diagnosis and treatment of elevated intracranial pressure (ICP) reduces morbidity rates and prevents mortality. The aim of the present systematic review and meta‑analysis was to determine the diagnostic accuracy of optic nerve sheath diameter (ONSD) vs. standard invasive ICP measurements in patients with traumatic brain injury (TBI). The PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for studies including adult patients with TBI with suspected elevated ICP, and the sonographic ONSD measurements were compared with those from a standard invasive method. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies‑2 tool by two independent authors. A bivariate random effects model was used to summarize the pooled sensitivity, specificity and diagnostic odds ratio (DOR). A total of eight prospective studies with 222 patients with TBI were included. The pooled sensitivity was 0.82 [95% confidence interval (CI), 0.75‑0.88], the specificity was 0.82 (95% CI, 0.71‑0.90) and the DOR was 17.75 (95% CI, 7.02‑44.83) with partial evidence of heterogeneity. The accuracy of the area under the summary ROC was 0.87. An ultrasound‑determined elevated ICP has reasonable performance indicators with high sensitivity and specificity in patients with TBI. As such, this method may be a useful complementary monitoring tool in acute care.
{"title":"Diagnostic accuracy of optic nerve sheath diameter on ultrasound for the detection of increased intracranial pressure in patients with traumatic brain injury: A systematic review and meta‑analysis","authors":"Weiting Chen, Xia Zhang, Xiuxiu Ye, Pan Ying","doi":"10.3892/br.2023.1685","DOIUrl":"https://doi.org/10.3892/br.2023.1685","url":null,"abstract":"The timely diagnosis and treatment of elevated intracranial pressure (ICP) reduces morbidity rates and prevents mortality. The aim of the present systematic review and meta‑analysis was to determine the diagnostic accuracy of optic nerve sheath diameter (ONSD) vs. standard invasive ICP measurements in patients with traumatic brain injury (TBI). The PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for studies including adult patients with TBI with suspected elevated ICP, and the sonographic ONSD measurements were compared with those from a standard invasive method. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies‑2 tool by two independent authors. A bivariate random effects model was used to summarize the pooled sensitivity, specificity and diagnostic odds ratio (DOR). A total of eight prospective studies with 222 patients with TBI were included. The pooled sensitivity was 0.82 [95% confidence interval (CI), 0.75‑0.88], the specificity was 0.82 (95% CI, 0.71‑0.90) and the DOR was 17.75 (95% CI, 7.02‑44.83) with partial evidence of heterogeneity. The accuracy of the area under the summary ROC was 0.87. An ultrasound‑determined elevated ICP has reasonable performance indicators with high sensitivity and specificity in patients with TBI. As such, this method may be a useful complementary monitoring tool in acute care.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"1 ","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136068062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：